TACROZEMUS

Tacrozemus

TACROZEMUS

Tacrolimus

Hiranis Pharmaceuticals (Pvt) Limited

Drug Identity

Active Ingredient
Tacrolimus
Drug Class
Antipsoriatics
ATC Code
D11AH01, L04AD02
Status
Essential Medicine

How to Take It

Dosage information not available for this product.

Safety Alerts

Application to malignant or potentially malignant skin lesions, application under occlusion, avoid contact with eyes and mucous membranes, congenital epidermal barrier defects, generalized erythroderma, immunodeficiency, infection at treatment site, pregnancy, lactation, hypersensitivity to macrolides

Important Warnings

Hepatic failure, avoid exposure to UV light
Treat infections before therapy
Monitor patients who develop lymphadenopathy

Side Effects

Application-site paininfections and reactionsherpes simplex infectionlocal irritationKaposis varicelliform eruptionacne. Rare: cutaneous lymphomaother types of lymphomasrosaceaskin malignancy

Drug Interactions

Avoid use of emollients within 2 hours
CYP3A4 inhibitors in widespread or erythrodermic disease
vaccines.

Price Intelligence

Rs 403.76
DVAGO observed price · as of 30 July 2026
No approved ceiling matched to this exact pack and strength.
Prices across sources
DVAGORs 403.76

Should you consider an alternative?

Other options containing Tacrolimus, and what they are not.You pay Rs 267 more than the cheapest equivalent

Identical active ingredient at the same strength. Cheapest per unit first.

Ordered by lowest price per unit where a pack size is known, then by price. Order is never affected by sponsorship. Not medical advice — confirm any change with your pharmacist or doctor.

For pharma professionalsCompany, market and opportunity intelligence

Company

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.